{"id":"tt3-lite-regimen-l-tt3","safety":{"commonSideEffects":[{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"L-TT3 works by replacing the thyroid hormone that is deficient in the body, thereby regulating metabolism and energy production. It is designed to mimic the natural T3 hormone, which is essential for various bodily functions. By replacing this hormone, L-TT3 helps to alleviate symptoms of hypothyroidism.","oneSentence":"L-TT3 is a thyroid hormone replacement therapy that mimics the natural thyroid hormone, T3.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:36.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypothyroidism"}]},"trialDetails":[{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Velcade (bortezomib)","Melphalan","Dexamethasone","Thalidomide","Cisplatin"],"phase":"phase_3","status":"active","brandName":"TT3-LITE Regimen (L-TT3)","genericName":"TT3-LITE Regimen (L-TT3)","companyName":"University of Arkansas","companyId":"university-of-arkansas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The TT3-LITE Regimen (L-TT3) is a treatment protocol studied in a clinical trial for patients with low-risk multiple myeloma. The trial, NCT00734877, is a Phase III study conducted by the University of Arkansas.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}